Pullen R H, Palermo K M, Curtis M A
Drug Disposition and Metabolism Department, ICI Americas Inc., Wilmington, DE 19897.
J Chromatogr. 1992 Jan 3;573(1):49-57. doi: 10.1016/0378-4347(92)80473-4.
ICI 204,636 (I) is an orally active antipsychotic agent under development for the treatment of schizophrenia in humans. It is partially converted in animals to an active 7-hydroxy metabolite (II). Methods were developed for the simultaneous determination of both analytes in human plasma using high-performance liquid chromatography (HPLC) and gas chromatography-mass spectrometry (GC-MS). The analytes were extracted from plasma using phenyl solid-phase extraction columns. Quantification by isocratic HPLC was performed in the reversed-phase mode with detection at 250 nm. Extracts were derivatized to trimethylsilyl ethers for quantification by GC-MS using selected-ion monitoring. Both assays were evaluated for consistency of response, precision, accuracy and specificity. Limits of quantification for I and II by HPLC were 15 and 20 ng/ml, respectively; limits of quantification for I and II by GC-MS were 2 and 5 ng/ml, respectively. Both methods were applied to the analysis of clinical samples from oral dosing studies with I.
ICI 204,636(I)是一种正在开发的口服活性抗精神病药物,用于治疗人类精神分裂症。它在动物体内部分转化为活性7-羟基代谢物(II)。采用高效液相色谱(HPLC)和气相色谱-质谱联用(GC-MS)技术,开发了同时测定人血浆中这两种分析物的方法。使用苯基固相萃取柱从血浆中提取分析物。等度HPLC定量分析在反相模式下进行,检测波长为250 nm。提取物经衍生化为三甲基硅醚,采用选择离子监测法通过GC-MS进行定量分析。对两种分析方法的响应一致性、精密度、准确度和特异性进行了评估。HPLC法测定I和II的定量限分别为15和20 ng/ml;GC-MS法测定I和II的定量限分别为2和5 ng/ml。两种方法均应用于I口服给药研究临床样品的分析。